November 2021

November 28, 2021

Identifying the best treatment strategy for Black or African American patients who are at risk for a more challenging clinical course is of great importance and represents a key unmet need in our field.

November 27, 2021

As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.

November 26, 2021

In line with the push for more comprehensive care, literature suggests that patients with multiple sclerosis benefit from physical therapy interventions to help manage disease symptoms.

November 26, 2021

The Bruton tyrosine kinase inhibitor has been evaluated in 2 phase 3 trials, GEMINI 1 and GEMINI 2 (NCT04410978; NCT04410991), in patients with relapsing-remitting and relapsing secondary progressive MS.

November 25, 2021

In a NeurologyLive® Peer Exchange series, experts on the care of patients with multiple sclerosis offer recommendations for selecting and sequencing therapies used to treat patients with relapsing disease.

November 25, 2021

The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.

August 25, 2021

The clinical research director of the UCSF Multiple Sclerosis Center shared his perspective on the history of clinical care for neuromyelitis optica spectrum disorder in light of 3 recent FDA approvals.